Hikma Pharmaceuticals (LON:HIK) Insider Purchases £123,600 in Stock

Posted by Lindsey Winhoffer on Aug 14th, 2026

Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) insider Tobias Hestler bought 7,500 shares of the stock in a transaction on Monday, August 10th. The shares were acquired at an average cost of GBX 1,648 per share, with a total value of £123,600.

Hikma Pharmaceuticals Trading Down 0.2%

HIK opened at GBX 1,643 on Friday. The company’s 50 day moving average is GBX 1,551.07 and its 200-day moving average is GBX 1,455.57. Hikma Pharmaceuticals PLC has a 1-year low of GBX 1,187 and a 1-year high of GBX 1,865. The company has a current ratio of 1.98, a quick ratio of 1.27 and a debt-to-equity ratio of 77.57. The company has a market cap of £3.43 billion, a P/E ratio of 9.08, a PEG ratio of 2.38 and a beta of 0.66.

Analyst Upgrades and Downgrades

HIK has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 1,950 target price on shares of Hikma Pharmaceuticals in a research report on Friday, August 7th. Jefferies Financial Group upped their price target on shares of Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Citigroup increased their price target on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the company a “buy” rating in a research note on Wednesday. Finally, Berenberg Bank raised their price objective on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a “buy” rating in a report on Tuesday. Six research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of GBX 2,060.

Get Our Latest Analysis on Hikma Pharmaceuticals

Hikma Pharmaceuticals Company Profile

(Get Free Report)

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.